MX2007016573A - Vacunas y peptidos terapeuticos. - Google Patents
Vacunas y peptidos terapeuticos.Info
- Publication number
- MX2007016573A MX2007016573A MX2007016573A MX2007016573A MX2007016573A MX 2007016573 A MX2007016573 A MX 2007016573A MX 2007016573 A MX2007016573 A MX 2007016573A MX 2007016573 A MX2007016573 A MX 2007016573A MX 2007016573 A MX2007016573 A MX 2007016573A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- composition according
- group
- hiv
- ccr5
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 98
- 229960005486 vaccine Drugs 0.000 title claims abstract description 29
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 31
- 230000027455 binding Effects 0.000 claims abstract description 60
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 14
- 230000002163 immunogen Effects 0.000 claims description 8
- KVPFYRAFNZKJSD-CPXLMRBJSA-N (2s,3r)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=C(O)C=C1 KVPFYRAFNZKJSD-CPXLMRBJSA-N 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 239000000061 acid fraction Substances 0.000 claims 6
- 125000003368 amide group Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 9
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 241001430294 unidentified retrovirus Species 0.000 abstract description 4
- 201000004681 Psoriasis Diseases 0.000 abstract description 3
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 abstract description 2
- 206010044696 Tropical spastic paresis Diseases 0.000 abstract description 2
- 208000006961 tropical spastic paraparesis Diseases 0.000 abstract description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000003960 inflammatory cascade Effects 0.000 abstract 1
- AKWRNBWMGFUAMF-ZESMOPTKSA-N (2s)-n-[(2s)-1-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-2-[[(2r)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amin Chemical compound C[C@@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(N)=O)CC1=CC=C(O)C=C1 AKWRNBWMGFUAMF-ZESMOPTKSA-N 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 32
- 230000003472 neutralizing effect Effects 0.000 description 31
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 27
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 23
- 230000002788 anti-peptide Effects 0.000 description 21
- 208000031886 HIV Infections Diseases 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 230000003612 virological effect Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 241000700605 Viruses Species 0.000 description 15
- 108010017088 CCR5 Receptors Proteins 0.000 description 14
- 102000004274 CCR5 Receptors Human genes 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 108010071384 Peptide T Proteins 0.000 description 13
- 102100034349 Integrase Human genes 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 9
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 101710091045 Envelope protein Proteins 0.000 description 7
- 101710188315 Protein X Proteins 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 108091008927 CC chemokine receptors Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000009410 Chemokine receptor Human genes 0.000 description 5
- 108050000299 Chemokine receptor Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 101710121417 Envelope glycoprotein Proteins 0.000 description 5
- 108090000189 Neuropeptides Proteins 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 230000010415 tropism Effects 0.000 description 5
- 108010041397 CD4 Antigens Proteins 0.000 description 4
- 102000001327 Chemokine CCL5 Human genes 0.000 description 4
- 108010055166 Chemokine CCL5 Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 238000002983 circular dichroism Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 102000005674 CCR Receptors Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 101000577064 Lymnaea stagnalis Molluscan insulin-related peptide 1 Proteins 0.000 description 3
- 101000737895 Mytilus edulis Contraction-inhibiting peptide 1 Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000035605 chemotaxis Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 101710205625 Capsid protein p24 Proteins 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 101150048348 GP41 gene Proteins 0.000 description 2
- 229940033330 HIV vaccine Drugs 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 101710177166 Phosphoprotein Proteins 0.000 description 2
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 2
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 101710149279 Small delta antigen Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102100022831 Somatoliberin Human genes 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 2
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 102000018265 Virus Receptors Human genes 0.000 description 2
- 108010066342 Virus Receptors Proteins 0.000 description 2
- -1 alkyl glycoside Chemical class 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000000954 titration curve Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 229940124718 AIDS vaccine Drugs 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 108700011778 CCR5 Proteins 0.000 description 1
- 101150017501 CCR5 gene Proteins 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229930195709 D-tyrosine Natural products 0.000 description 1
- 125000002849 D-tyrosine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940126154 HIV entry inhibitor Drugs 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033332 HIV-1 vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 101000980744 Homo sapiens C-C chemokine receptor type 3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101900082162 Human immunodeficiency virus type 1 group M subtype B Surface protein gp120 Proteins 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229910025794 LaB6 Inorganic materials 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 101000897431 Macaca mulatta C-C chemokine receptor type 5 Proteins 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 241000411141 North American clade Species 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241001417495 Serranidae Species 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 description 1
- 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 210000000540 fraction c Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000002835 hiv fusion inhibitor Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000028802 immunoglobulin-mediated neutralization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000028550 monocyte chemotaxis Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108010030416 proteoliposomes Proteins 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69308805P | 2005-06-23 | 2005-06-23 | |
| US69308905P | 2005-06-23 | 2005-06-23 | |
| US69308705P | 2005-06-23 | 2005-06-23 | |
| PCT/US2006/024580 WO2006138745A2 (en) | 2005-06-23 | 2006-06-23 | Therapeutic peptides and vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007016573A true MX2007016573A (es) | 2008-10-17 |
Family
ID=37571305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007016573A MX2007016573A (es) | 2005-06-23 | 2006-06-23 | Vacunas y peptidos terapeuticos. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7700115B2 (enExample) |
| EP (1) | EP1893233A4 (enExample) |
| JP (1) | JP2008546803A (enExample) |
| KR (1) | KR20080019720A (enExample) |
| AU (1) | AU2006261133B2 (enExample) |
| BR (1) | BRPI0611927A2 (enExample) |
| CA (1) | CA2624957A1 (enExample) |
| MX (1) | MX2007016573A (enExample) |
| WO (1) | WO2006138745A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1893233A4 (en) | 2005-06-23 | 2010-03-31 | Rapid Pharmaceuticals Ag | PEPTIDES AND THERAPEUTIC VACCINES |
| US8178497B2 (en) | 2007-11-14 | 2012-05-15 | Rapid Pharmaceuticals Ag | Method of treating HIV in drug resistant non plasma viral reservoirs with monomeric DAPTA |
| US10130674B2 (en) * | 2010-02-09 | 2018-11-20 | Creative Bio-Peptides | Modified peptide that reduces pain in peripheral neuropathy |
| US9040046B2 (en) | 2011-01-31 | 2015-05-26 | Kai Xu | Sodium pump antibody agonists and methods of treating heart disease using the same |
| US20140092376A1 (en) * | 2012-10-01 | 2014-04-03 | Momentive Performance Materials, Inc. | Container and method for in-line analysis of protein compositions |
| US20140322251A1 (en) * | 2013-04-26 | 2014-10-30 | Michael Ruff | Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions |
| US20180344798A1 (en) * | 2017-05-31 | 2018-12-06 | Creative Bio-Peptides Inc. | Topically active peptides for treating cosmetic and dermatological conditions |
| USRE50630E1 (en) | 2017-10-31 | 2025-10-14 | Creative BioPeptides, Inc. | Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain |
| US11510961B2 (en) | 2019-12-19 | 2022-11-29 | Creative Bio-Peptides, Inc. | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof |
| US20210244788A1 (en) * | 2020-02-06 | 2021-08-12 | Creative Bio-Peptides Inc. | Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3689941D1 (de) * | 1985-10-24 | 1994-08-04 | Southwest Found Biomed Res | Synthetische peptide und deren verwendung zur diagnose und impfung für aids und arc. |
| AU7544987A (en) * | 1986-06-03 | 1988-01-11 | Pert, C.B. | Small peptides which inhibit binding to t-4 receptors |
| US6242564B1 (en) | 1986-06-03 | 2001-06-05 | Candace B. Pert | Treatment of tropical spastic paresis with peptide T |
| CA1341066C (en) * | 1986-06-03 | 2000-08-01 | Candace B. Pert | Small peptides which inhibit binding to t-4 receptors and act as immunogens |
| US5276016A (en) * | 1986-06-03 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Small peptides which inhibit binding to T-4 receptors and act as immunogens |
| US5063206A (en) | 1988-12-16 | 1991-11-05 | The United States Of Americas As Represented By The Department Of Health And Human Services | Compositions having use as treatment of neuropsychiatric deficits |
| US5739109A (en) | 1988-12-16 | 1998-04-14 | Advanced Immunit Inc. | Method of treating neuroinflammatory degenerative diseases |
| US6011014A (en) | 1992-03-27 | 2000-01-04 | Advanced Immunit, Inc. | Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis |
| DK64592D0 (da) | 1992-05-14 | 1992-05-14 | Carlbiotech Ltd As | Peptider til terapeutisk behandling |
| US5534495A (en) | 1993-05-25 | 1996-07-09 | Advanced Peptides And Biotechnology Sciences | Treatment of non-HIV neuropathic pain syndromes |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US20040126811A1 (en) * | 2002-02-21 | 2004-07-01 | Thomas Boren | Helicobacter pylori sialic acid binding adhesin, saba and saba-gene |
| WO2007002465A2 (en) | 2005-06-23 | 2007-01-04 | Rapid Pharmaceuticals, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| EP1893233A4 (en) | 2005-06-23 | 2010-03-31 | Rapid Pharmaceuticals Ag | PEPTIDES AND THERAPEUTIC VACCINES |
-
2006
- 2006-06-23 EP EP06785485A patent/EP1893233A4/en not_active Withdrawn
- 2006-06-23 BR BRPI0611927-1A patent/BRPI0611927A2/pt not_active IP Right Cessation
- 2006-06-23 KR KR1020087001808A patent/KR20080019720A/ko not_active Ceased
- 2006-06-23 AU AU2006261133A patent/AU2006261133B2/en not_active Ceased
- 2006-06-23 US US11/426,301 patent/US7700115B2/en active Active - Reinstated
- 2006-06-23 JP JP2008518460A patent/JP2008546803A/ja active Pending
- 2006-06-23 CA CA002624957A patent/CA2624957A1/en not_active Abandoned
- 2006-06-23 WO PCT/US2006/024580 patent/WO2006138745A2/en not_active Ceased
- 2006-06-23 MX MX2007016573A patent/MX2007016573A/es active IP Right Grant
-
2010
- 2010-01-16 US US12/688,862 patent/US10071153B2/en active Active
-
2018
- 2018-08-03 US US16/054,455 patent/US10973906B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2624957A1 (en) | 2006-12-28 |
| AU2006261133A1 (en) | 2006-12-28 |
| WO2006138745A3 (en) | 2007-11-29 |
| WO2006138745A2 (en) | 2006-12-28 |
| EP1893233A4 (en) | 2010-03-31 |
| JP2008546803A (ja) | 2008-12-25 |
| US20060292167A1 (en) | 2006-12-28 |
| BRPI0611927A2 (pt) | 2011-08-16 |
| US10071153B2 (en) | 2018-09-11 |
| US7700115B2 (en) | 2010-04-20 |
| AU2006261133B2 (en) | 2012-04-05 |
| KR20080019720A (ko) | 2008-03-04 |
| US20100184705A1 (en) | 2010-07-22 |
| US10973906B2 (en) | 2021-04-13 |
| EP1893233A2 (en) | 2008-03-05 |
| US20190000964A1 (en) | 2019-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10973906B2 (en) | Therapeutic peptides and vaccines | |
| Koch et al. | Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition | |
| Xiang et al. | Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies | |
| Basmaciogullari et al. | Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding | |
| Dowbenko et al. | Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies | |
| Lusso et al. | Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains | |
| Yuan et al. | CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor | |
| WO1999024465A9 (en) | Stabilized primate lentivirus envelope glycoproteins | |
| Borkow et al. | Multi-targeting the entrance door to block HIV-1 | |
| CA2305341C (en) | Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain | |
| WO1998000535A2 (en) | Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection | |
| Lagenaur et al. | sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates | |
| AU731975B2 (en) | GP120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting HIV infection | |
| WO1998015569A9 (en) | Gp120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting hiv infection | |
| CN101242854A (zh) | 治疗肽及疫苗 | |
| Jekle et al. | CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency | |
| McKnight et al. | Clade specific neutralising vaccines for HIV: an appropriate target? | |
| Meta et al. | Inhibition of M-tropic HIV-1 infection by the fd phage-gene 3 protein with MIP-1α-binding activity | |
| Couto | Synthetic antibodies targeting HIV-1 infectivity | |
| Hung | The role of HIV-1 V3 loop in CCR5 tropism and macrophage infection | |
| Poli | Chemokines and the human immunodeficiency virus | |
| Guenaga | Epitope Scaffolds And The HIV-1 gp41 2F5 Neutralization Determinant | |
| Beirnaert | Broad cross-neutralisation in HIV-infected individuals | |
| PANTALEO et al. | Retroviral Immunology | |
| Yen | SIV envelope glycoprotein determinants of macrophage tropism and their relationship to neutralization sensitivity and CD4-independent cell-to-cell transmission |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |